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The current gold standard for assessing glycaemic control is 
measure ment of glycated haemoglobin (HbA1c).[1] However, there 
are numerous caveats associated with using HbA1c to guide treat­
ment adjustments, including inability to inform on the timing of 
hyperglycaemia.[2] Additionally, the National Health Laboratory 
Service allows for HbA1c to be tested twice a year for controlled 
patients in government healthcare facilities in South Africa (SA) 
and four times a year for poorly controlled patients,[3] but results are 
routinely delayed by up to 8 weeks. Infrequent therapy adjustments 
are therefore being made based on outdated glycaemic data. Self­
monitoring of blood glucose (SMBG) serves as an alternative tool to 
assess diabetes control and guide more regular medication changes.[4]
The purpose of SMBG is to collect detailed information about 
glucose levels across various time points each day.[2] Most importantly, 
SMBG data can be made available at each clinical consultation 
without delay, thus guiding therapy adjustments within the same 
consultation.[5] However, there is currently no standardised approach 
to utilising SMBG data to improve glycaemic control in patients with 
type 2 diabetes.[6] The success of SMBG is expected to be minimal if 
it is not accompanied by medication dose titration to target specific 
hyperglycaemic patterns identified.[7]
For a variety of conditions, such as HIV or tuberculosis, outcomes 
with dose titration protocols are superior to those achieved by 
individualisation of care.[8] This may be true for type 2 diabetes 
owing to both hesitation of physicians[9] and reluctance of patients[10] 
to initiate and/or titrate insulin because of the fear of hypoglycaemia 
and weight gain.
Objectives
To assess the improvement in glycaemic control when a structured 
SMBG schedule in combination with an insulin titration algorithm 
was used for patients with type 2 diabetes. Glycaemic control was 
primarily investigated by change in HbA1c, and secondly by change 
in mean SMBG and mean fasting plasma glucose (FPG) levels.
Methods
Participants
The study was a 6­month prospective, non­randomised, single­group 
trial in patients with type 2 diabetes using twice­daily biphasic human 
insulin 30 (30% human insulin and 70% neutral protamine Hagedorn 
insulin). Participants were recruited from outpatient diabetic clinics 
at Steve Biko Academic Hospital and Kalafong Hospital in Tshwane, 
SA. Each healthcare facility reviewed all patient records to create a 
list of patients with recorded HbA1c ≥8.5% (69.4 mmol/mol) in the 
preceding 6 months. Patients were then randomly selected from the 
list and invited to a screening visit via telephone call.
Inclusion criteria were duration of type 2 diabetes >1 year, age 
18 ­ 75 years, HbA1c ≥8.5% (69.4 mmol/mol), currently treated 
with ≥1 insulin injection per day and having voluntarily signed the 
informed consent document. Exclusion criteria were type 1 diabetes, 
having participated in any other research protocol within the past 30 
days, current use of oral hypoglycaemic agents other than metformin, 
a history of cancer within the past 5 years, current chemotherapy 
or radiation therapy, plans to relocate or travel extensively during 
the following 6 months, pregnancy or breastfeeding, ≥1 severe 
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hypoglycaemic episode(s) within the past 6 
months that resulted in hospital admission 
and/or coma, severe depression or other 
severe psychological conditions, a history 
of chronic kidney disease, a history of 
heart failure where cardiovascular status 
was unstable, manual or visual disability 
that required dependence on others to 
give insulin or to document blood glucose 
values, major surgery scheduled within 
6  months of enrolment and current use of 
oral corticosteroids.
Ethical approval was obtained from the 
Health Sciences Research Ethics Committee 
of the University of Pretoria (ref. no. 
432/2014). The trial was registered with the 
Department of Health on the South African 
National Clinical Trials Register (ref. no. 
DOH­27­0115­4949) and the International 
Standard Randomised Controlled Trials 
Number registry (ref. no. ISRCTN13215752).
At the screening appointment, investiga­
tors obtained written informed consent 
before collecting baseline demographic, 
medical and clinical information, including 
HbA1c. Patients who met all the inclusion 
criteria were enrolled into the study until 
the predetermined sample size was achieved.
Procedures
The duration of the study was 6 months. 
Patient visits occurred monthly to coincide 
with days when the participant came to 
the hospital to collect their chronic 
medication. At the baseline visit, patients 
received a blood glucose meter (Accu­Chek 
Active blood glucose meter system; Roche 
Products, SA) and were thoroughly trained 
in its operation with the aid of pictures to 
assist those with low literacy levels. Research 
staff provided patients with test strips and 
a diary to record blood glucose values as 
per the structured SMBG routine. Patients 
were also educated in the use of metered 
dosing flex pens to administer accurate 
insulin doses. Assessment of quality of life 
(QoL) was conducted using the Diabetes 
Treatment Satisfaction Questionnaire 
(DTSQ) at baseline and study end.[11] No 
diabetes­related treatment changes occurred 
at the baseline visit.
Intervention
Patients were asked to perform four blood 
glucose tests per day for 3 consecutive days 
of each week. Fig. 1A specifies how blood 
glucose tests were distributed to encompass 
different time points throughout the day. 
SMBG testing was staggered to include 
weekdays and weekends. This resulted 
in a total of 48 blood glucose tests per 
month. At each consultation, SMBG results 
were downloaded using the Accu­Chek 
SmartPix software (Roche Products, SA). 
SMBG results and targets were discussed 
with the patient, emphasising the timing of 
hyperglycaemia.
The insulin titration protocol used by 
Liebl et al.[12] (p. 47) with aspects from 
the Canadian Diabetes Association clinical 
guidelines[13] and the Canadian Agency for 
Drugs and Technologies in Health report[14] 
was used to create the algorithm applied in 
this study, as described in Fig. 1B. Insulin 
doses were titrated to achieve glycaemic 
targets; however, if deemed inappropriate 
by the physician, reasons for not using 
the algorithm were recorded. If patients 
had experienced hypoglycaemic events in 
the preceding month, identification and 
treatment of low blood glucose was also 
discussed with the patient. The following 
glycae mic targets were used: (i) FPG: 5.0 ­ 
7.2 mmol/L; (ii) 2­hour post­prandial glu cose 
<10.0 mmol/L; (iii) average glucose (mean 
SMBG) <8.6 mmol/L; and (iv) HbA1c  <7% 
(53 mmol/mol).
Statistical analysis
The study was designed to have 90% 
power to detect an absolute mean within­
subject HbA1c difference of 1.0% over the 
intervention using three observations per 
patient (baseline and 3 and 6 months). This 
was determined using the Hotelling­Lawley 
trace (HLT) test for repeated measures 
(two­sided, α=0.05), assuming a mean base­
line HbA1c of 9.0% (75 mmol/mol) and 
standard deviation of 2.2%.[14] According 
to these specifications, a sample size of 32 
participants with complete data (i.e. all three 
observations) was needed. To account for 
missing data and loss to follow­up, a 20% 
attrition rate was assumed, resulting in a 
recommended sample size of 40 participants. 
By using three observations, the HLT 
test allowed for a smaller sample size to 
test the null hypothesis due to repeated 
HbA1c sampling. In contrast, if only two 
observations were used (for example, HbA1c 
at pre­ and post­intervention), paired t­test 
analysis would have required 64 patients 
for the study. Owing to tight budgetary 
constraints, the HLT test was therefore 
selected. This choice then necessitated 
the use of either multivariate analysis of 
variance (MANOVA) or generalised linear 
mixed modelling (GLMM) in the analysis 
of dependent variables with three or more 
observations. GLMM was favoured over 
MANOVA owing to its ease in between­
subject covariate handling and increased 
efficiency in handling missing data.[15]
GLMM assumptions include: (i) that the 
dependent variable (HbA1c) is a normally 
distributed, continuous variable; (ii) that 
the residuals of the dependent variable are 
normally distributed; (iii) that at least 10% of 
the total variance in the dependent variable 
must be explained at the level 2 variable 
(i.e. patient level in this study); (iv) that 
the relationship between the mean of the 
dependent variable and the fixed and random 
effects can be modelled through a linear 
function; and (v) that dependent variable 
variance is not a function of its mean.
The final model conformed to these 
assumptions, with the exception of normally 
distributed residuals. Regarding the second 
assumption, Gelman and Hill[16] note that 
the normality of residuals does not affect the 
parameter estimates in multilevel models, 
and therefore advise against normality tests.
Data for which only two observations 
were made (pre­ and post­intervention) 
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Fig. 1. (A) The newly designed structured SMBG routine with a total of 48 tests performed per month. 
(B) Insulin titration algorithm used to target hyperglycaemia identified by structured SMBG. (SMBG = 
self-monitoring of blood glucose; X = SMBG performed; FPG = fasting plasma glucose.)
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were tested using a paired t­test if normally 
distributed (for example, change in weight) 
or the Wilcoxon signed­rank test if not 
normally distributed (for example, change 
in QoL).
Main outcome measures
HbA1c was assessed on site using the Cobus 
B101 (Roche Products, SA) at three time 
points, namely baseline, 3 months and 
6 months. Sensitivity analysis was conduc­
ted for participants with a baseline HbA1c 
≥10% (86 mmol/mol). Mean SMBG and 
mean FPG were assessed per monthly 
visit over six time periods using the mean 
of all blood glucose values and the mean 
SMBG tests performed before breakfast, 
respec tively. Compliance was analysed as 
a categorical variable where patients were 
divided into quartiles according to the total 
number of SMBG tests performed from 
a maximum of 288 throughout the study 
period.
The analysis of trend in HbA1c, mean 
SMBG and mean FPG was performed using 
GLMM with the XTMIXED command in 
Stata to assess changes between relative time 
periods.[17] Participant age, gender, race and 
number of SMBG tests performed were 
evaluated as fixed effects; visit number and 
subject were set as random effects. Random 
intercept and random slope were modelled 
for all dependent variable analyses. Based on 
the mixed model, the least squares estimates 
of the time interval differences were obtained 
and tested for statistical significance. No 
missing data were imputed.
Change in morning and evening insulin 
doses (pre­ and post­intervention) were 
analysed using paired t­test analyses with 
equal and unequal variance, respectively. 
Qualitative analysis was undertaken for 
situations where the algorithm was deemed 
inappropriate. Change in weight was 
calculated using a paired t­test of differences 
in baseline and final mass of the participants.
The incidence rate of hypoglycae­
mic events (defined as blood glucose 
<4.0  mmol/L) was calculated as [(total 
number of events across all participants)/
(total duration of treatment in years across 
all participants)]. Median number of hypo­
glycaemic episodes was also reported.
Analysis of change in QoL data was 
assessed from the Likert scale items 
(range 0 ­ 6) in the eight­item DTSQ, with 
higher scores indicating greater treatment 
satisfaction. Change in treatment satisfaction 
was calculated as the sum of items 1 and 
4 ­ 8 on the DTSQ, and differences in 
pre­ and post­intervention were evaluated 
using the Wilcoxon signed­rank test. 
Change in perceived hyperglycaemia (item 
2 on the DTSQ) and change in perceived 
hypoglycaemia (item 3 on the DTSQ) were 
evaluated using paired t­tests for pre­ and 
post­intervention scores.
Results
A total of 59 patients were screened for 
the study, of whom 40 were enrolled; 35 
were treated at Kalafong District Hospital 
and 5 at Steve Biko Academic Hospital. 
Fig. 2 describes the patient flow within the 
study. One patient was lost to follow­up 
owing to relocation to a different province 
after 3 weeks into the study. No insulin 
titrations were made, so the patient’s 
results were excluded from all calculations. 
Table 1 describes baseline demographic and 
clinical characteristics of the 39 patients 
who completed the trial. There were no 
intervention­related adverse events.
Glycaemic control
GLMM analysis revealed that a mean 
(standard error (SE)) reduction of 1.89% 
(0.289) in HbA1c level was achieved over 
the 6­month intervention (95% confidence 
interval (CI) –2.46 ­ –1.33; p<0.001). Chan­
ges in HbA1c statistics over the various time 
Table 1. Baseline demographic and clinical characteristics of the study participants
Characteristic Study sample
Patient age (years), mean (SD) 58.8 (6.5)
Male, n (%) 13 (33.3)
Ethnicity, n (%)  
Black 28 (71.8)
White 4 (10.2)
Coloured 4 (10.2)
Indian 3 (7.7)
HbA1c (%), mean (SD) 10.69 (1.69)
BMI (kg/m2), mean (SD) 34.9 (7.6)
Diabetes duration (years), mean (SD) 17.6 (8.2)
Smoking status, n (%)  
Never 29 (74.4)
Ex­user 9 (23.1)
Current 1 (2.5)
Hypertensives, n (%) 37 (94.9)
Hypertension duration (years), mean (SD) 14.7 (9.3)
SD = standard deviation; HbA1c = glycated haemoglobin; BMI = body mass index.
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Assessed for eligibility, N=59
Allocated to intervention, n=40
Received allocated intervention, n=39
Lost to follow-up, n=0
Discontinued intervention, n=0
Analysed, n=39
Excluded from analysis, n=0
Excluded, n=19
HbA1c <8.5%, n=11
Severe hypoglycaemic episode in past 6 months, n=1
Not able to travel to clinic every month, n=2
Weary of insulin titration, n=1
Major surgery scheduled within the next 6 months, n=2
Personal reasons, n=2 
Did not receive allocated intervention, 
n=1 (relocation to another province)
Fig. 2. Patient flow within the study. (HbA1c = glycated haemoglobin.)
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intervals are presented in Table 2. The greatest reduction in HbA1c 
was achieved in the first 3 months of the intervention. A total of 
4  patients (10.25%) achieved a target HbA1c of <7.0% (53 mmol/
mol). Sensitivity analysis showed a significantly larger reduction 
in HbA1c (–2.29%) in patients with a baseline HbA1c ≥10.0% (86 
mmol/mol) in comparison with those with a baseline HbA1c ≤9.9% 
(85 mmol/mol) (–1.26%; p<0.001, GLMM). All patients in the sample 
attended 100% of the seven clinical visits. Mean patient compliance 
with the SMBG regimen was >70% at each month. No statistically 
significant difference in HbA1c reduction was found for patients 
allocated to different compliance quartiles (p=0.062, GLMM).
Study participants achieved a significant reduction in mean SMBG 
of 1.6 mmol/L (95% CI –2.5 ­ –0.6; p=0.002) from a baseline value of 
10.9 mmol/L. Fig. 3A shows the trend in mean SMBG with associated 
95% CI for each month of the study. Analysis demonstrated that 
mean FPG decreased significantly from 9.5 mmol/L to 8.5 mmol/L 
over the study period, resulting in a mean reduction of 1.0 mmol/L 
(95% CI –2.2 ­ –0.2; p=0.024). Fig. 3B shows the trend in FPG 
change per month of the study.
Insulin dose
Paired t­test analysis of pre­ and post­intervention insulin doses 
indicated that both mean pre­breakfast and pre­dinner insulin 
doses increased significantly over the 6­month study period. Table 3 
describes these titration changes. Mean total daily insulin was found 
to increase from 67.76 to 107.89 units (37.19% increase, SE 7.7; 
p<0.001, unequal paired t­test).
Throughout the study period, a total of 234 consultations with 
insulin titration were performed. Of those consultations, 22 (9.4%) 
occurred where it was deemed inappropriate to use the insulin 
titration algorithm. Reasons for these decisions were grouped into 
the following: insufficient data to make informed titration decisions 
(n=11); patient not taking new prescribed doses recommended at the 
previous visit (n=4); patient taking insulin doses at the incorrect time 
(n=3); SMBG showing excessive intraday variability (n=4); patient 
placed on separate regimens for day/night shifts (n=2); and patient 
diagnosed with renal failure requiring dose reduction (n=1).
The titration algorithm did not allow for sufficient reduction 
in insulin doses when frequent hypoglycaemia occurred, rather 
advising that no insulin adjustment be made if two hypoglycaemic 
events occurred in 1 week or if nocturnal hypoglycaemia had 
occurred during any point in the previous month (Fig. 1B). 
More over, patients were never observed to have a mean FPG or 
pre­dinner values of ≤4.0 mmol/L as would be required by the 
algorithm to decrease the insulin dose. For this reason, it was 
deemed appropriate to reduce insulin dose by 2 units if three or four 
hypoglycaemic episodes had occurred at the same meal time during 
the previous month or by 4 units if five or more hypoglycaemic 
episodes had occurred at the same meal time.
Hypoglycaemia
The incidence of hypoglycaemia (defined as <4.0 mmol/L) based on 
downloaded SMBG data was 33.08 events per patient year, with a 
median of 13 events per patient (interquartile range 3 ­ 26) over the 
6­month intervention. Eight patients (20.5%) contributed to 52.7% of 
all hypoglycaemic events. Each of these patients had at least 1 month 
when they experienced ≥10 hypoglycaemic episodes. The majority of 
the low blood glucose levels occurred in the last 3 months of the trial. 
Most hypoglycaemic episodes were recorded within the specified 
SMBG regimen time points. No hypoglycaemic events required 
hospitalisation, and patients did not require third­party assistance 
in any event.
Body weight
Mean weight increased by 3.98 kg (95% CI 2.56 ­ 5.41; p<0.001, 
GLMM) over the study period.
Table 2. Change in HbA1c over various time points
Time
HbA1c (%)
Mean SD Range
Baseline 10.69 1.69 8.5 ­ 14.0*
3 months 9.1 1.26 6.5 ­ 12.0
6 months 8.8 1.42 6.7 ­ 12.1
HbA1c = glycated haemoglobin; SD = standard deviation.
*The maximum recordable HbA1c on the Cobus B101 was 14.0%.
Table 3. Titration of insulin doses at each clinical visit
Visit
Mean insulin dose change (units/day) (SD)
Morning Evening Total
1 2.0 (5.8) 3.64 (6.3) 10.0 (10.3)
2 5.97 (5.2) 4.10 (7.1) 10.1 (10.0)
3 5.12 (4.4) 4.61 (5.8) 9.7 (8.6)
4 3.15 (4.4) 1.59 (3.6) 4.7 (6.7)
5 2.92 (4.4) 2.64 (5.3) 5.6 (7.6)
Total 23.5 (12.7) 16.6 (20.4) 40.1 (28.6)
SD = standard deviation.
Fig. 3. Changes in (A) mean SMBG and (B) mean FPG over the 6-month 
study period. Dotted lines show 95% CIs for values. (SMBG = self-monitor-
ing of blood glucose; FPG = fasting plasma glucose; CI = confidence interval.)
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Quality of life
The difference in pre­ and post­trial treatment satisfaction and 
perceived hyperglycaemia was found to be non­significant (p=0.2717, 
Wilcoxon signed­rank test; p=0.1156, paired t­test, respectively). 
Difference in perceived hypoglycaemia scores was found to be 
significantly raised after the intervention (p=0.0251, paired t­test).
Discussion
Structured SMBG paired with monthly algorithmic insulin titration 
was effective in significantly reducing HbA1c in patients with type 
2 diabetes using biphasic insulin. Glycaemic improvement was 
greatest in patients with a baseline HbA1c ≥10.0% (86 mmol/mol).
HbA1c improvement can be attributed to the significant reduc­
tion in mean SMBG and mean FPG resulting from increased 
frequency of insulin titrations. Monnier et al.[18] found that in patients 
with HbA1c ≥8.4% (≥68 mmol/mol), overall hyperglycaemia was 
predominantly attributed to FPG excursions. The improvement in 
HbA1c achieved in the current study was comparable to[19] and even 
better than[12,20,21] similar insulin titration studies. Patients with poorer 
baseline glycaemic control achieved a larger reduction in HbA1c 
owing to the larger range over which to improve blood glucose 
levels before reaching glycaemic targets. Most HbA1c reduction 
was attributed to the first 3 months of the intervention, as seen in 
Fig. 3A. During this time, insulin doses were aggressively titrated by 
using larger (even maximum) dose increments permitted within the 
algorithm, compared with later dose adjustments. This is expected, 
as the algorithm allows for smaller adjustments as patients achieve 
SMBG levels closer to target. It follows that, if resources are severely 
limited, it may be beneficial to enrol patients into this intervention 
for only 3 months and still achieve significant glycaemic reductions.
Additional factors that may have contributed to glycaemic 
improvement are increased frequency of clinical consultations, the 
use of free meters and strips that were consistently made available, 
and the practice of downloading SMBG data. This is supported by 
the fact that four participants had maximum recordable baseline 
HbA1c values (>14% or 130 mmol/mol), yet only one patient had 
a mean SMBG in the first month to warrant such high glycated 
haemoglobin levels (18.9 mmol/L), suggesting that these factors 
may have been indirectly addressed due to enrolment in the trial.[22]
The small reduction in mean SMBG (–1.6 mmol/L) did not 
reflect the reduction in HbA1c achieved over the study period. 
From the international A1c­Derived Average Glucose trial, a mean 
reduction in HbA1c of 1.89% should have yielded a mean SMBG 
reduction of 3.0 mmol/L.[23] It is therefore assumed that total 
glucose variations were not captured by the SMBG routine, which 
can be expected, since only 144 glucose measurements per HbA1c 
measurement were used.
Wei et al.[24] established specific SMBG values throughout the day 
associated with HbA1c outcomes, and found that for patients who 
had achieved an HbA1c of 8.0 ­ 8.5% (64 ­ 69 mmol/mol), mean 
FPG was estimated as 9.9 mmol/L (95% CI 9.1 ­ 10.7).[24] This may 
explain why a relatively small decrease in FPG (–1.0 mmol/L) in the 
current study produced moderate changes in HbA1c.
The magnitude of insulin titration was unprecedented, with 
patients increasing their mean total daily dose by 37.2% by the 
end of the study period. The National Institute for Health and 
Care Excellence indicates that there is no theoretical upper limit to 
insulin doses.[25] This observation implies that the current standard 
practice of minor insulin adjustments (for example, adding 2 ­ 
4  units) made every 3 months is grossly inadequate to achieve 
improved glycaemia in type 2 diabetes patients on insulin. The 
large standard deviations seen in Table 3 show the flexibility of the 
algorithm to accommodate the different needs of each patient.
Most hypoglycaemic events were recorded when patients were 
scheduled to perform SMBG, so the risk of hypoglycaemia is 
likely to be under­reported. Additionally, blood glucose levels 
were not measured during the night, a period when participants 
were at risk owing to the peak of biphasic insulin action occurring 
2 ­ 4 hours after dinner.[26] A large proportion of hypoglycaemic 
events were attributed to only eight patients, but they shared no 
commonalities. The incidence of hypoglycaemia was significantly 
higher than in other titration studies; however, not all these 
studies used the conventional definition of <4.0 mmol/L to define 
hypoglycaemia. [12,19,20] Weight gain during the intervention was 
predicted, as is seen when increasing insulin doses due to a decrease 
in basal metabolic rate, a decrease in glycosuria, and increased 
caloric intake for the treatment of hypoglycaemia.[27] A concern is 
that the mean 3.98 kg gain may have a significant impact in terms 
of increasing risk for cardiovascular disease.[28] Weight gain in the 
current study was slightly greater than observed in some insulin 
titration studies,[12,21] but markedly lower than in others.[19,20]
The DTSQ identified an increase in perceived burden of hypo­
glycaemia. This is expected, because increased SMBG fre quency 
may reveal asymptomatic hypoglycaemia and contribute to 
increased awareness of glucose fluctuations.[29] Patients are also 
expected to experience more frequent hypoglycaemia as they 
approach glycaemic targets.
Adjustments to the intervention
Several changes to both the SMBG regimen and the titration 
algorithm are recommended. The authors suggest removal of all 
12 post­prandial SMBG tests, since none of these results were utilised 
by the titration algorithm to adjust insulin doses, and patients also 
found it difficult to remember to test their blood glucose levels 
2 hours after eating. Additionally, biphasic insulin is unable to 
effectively alter post­prandial glucose excursions, which contribute 
less to overall hyperglycaemia in patients with high HbA1c values. [18] 
Titration of insulin only required 50% of SMBG tests to be performed 
to have sufficient data to inform insulin adjustments. This was 
shown by equivalent HbA1c reductions in patients in the second and 
third quartile of compliance compared with those with enhanced 
compliance. It was also noted that patients complained of excessive 
SMBG tests, so reducing the number of prescribed tests may increase 
compliance. From these arguments, the researchers recommend that 
the structured SMBG regimen be reduced to a total of 16 tests over 
a period of 4 days prior to the patient’s clinical consultation and/or 
collection of chronic medication, namely before each main meal and 
before bedtime each day. This will allow sufficient data on which to 
titrate insulin doses, accounting for a 70 ­ 80% compliance rate.
The titration algorithm was found to be significantly effective in 
reducing HbA1c during the intervention; however, it did not allow 
for appropriate dose reductions for multiple hypoglycaemic events 
experienced over the same meal times. As was implemented in the 
study, if during the previous month patients were found to have 
3 ­ 4 hypoglycaemic events during the same meal time, insulin was 
reduced by 2 units; patients having ≥5 hypoglycaemic events at the 
same meal times had dose reductions of 4 units.
Application to clinical practice
The unprecedented increase in insulin doses for participants in this 
study points to the novel finding that current insulin titration in 
patients with type 2 diabetes is vastly inadequate. The advantage 
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of this intervention is that an insulin titration algorithm is easy to 
follow for healthcare professionals who have limited experience 
with diabetes, while not reducing the doctor’s autonomy to override 
the recommendation set forth. The consistency of care may assist 
diabetes clinics to efficiently reach glycaemic targets for most 
patients. Since this study did not enrol patients taking concomitant 
sulphonylurea agents, the authors recommend caution when applying 
this titration algorithm to such patients.
Study limitations
There were several limitations to the study. Firstly, the lack of a control 
group means that we cannot explicitly state that this intervention 
truly improved glycaemic control beyond current practice. To 
confirm the true benefit of this intervention, it is recommended that 
a sufficiently powered randomised controlled trial be conducted. 
Secondly, we could not confirm that the recommended insulin 
titration changes occurred as prescribed. Thirdly, we cannot assess 
whether improvement of glycaemic control was maintained after the 
intervention. Lastly, the small sample size limits generalisability of 
the findings.
Conclusions
Structured SMBG that advises monthly algorithmic insulin titration 
can significantly improve glycaemic control in type 2 diabetes 
patients using twice­daily biphasic insulin by aggressively increasing 
insulin doses, with moderate hypoglycaemic events and weight gain. 
This research allows for greater confidence in healthcare practitioners 
to safely titrate insulin in this population owing to the immense 
increase in doses observed. It is recommended to assess this study 
in a cluster randomised clinical trial in order to ensure accuracy and 
generalisability of results.
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